Table 3 Cox multivariate analysis of recurrence/mortality in patients with tamoxifen monotherapy

PostM vs. PreM

1.048 (0.671-1.665)

0.8404

1.154 (0.728-1.879)

0.5482

1.464 (0.561-4.045)

0.4367

1.523 (0.542-4.585)

0.4255

T (>2cm vs. ≤2cm)

1.921 (1.232-3.097)

0.0035*

1.637 (1.016-2.726)

0.0426

4.859 (1.334-31.224)

0.0137*

4.370 (1.165-28.412)

0.0268

LN (+ vs. -)

3.004 (1.953-4.736)

<0.0001*

3.466 (2.118-5.898)

<0.0001*

1.851 (0.664-5.160)

0.2342

2.438 (0.822-7.620)

0.1075

Grade (II+III vs. I)

1.810 (1.165-2.887)

0.0079*

1.902 (1.184-3.147)

0.0074*

1.296 (0.414-4.933)

0.6696

1.447 (0.454-5.593)

0.5464

ER (+ vs. -)

1.128 (0.634-2.092)

0.6890

PR (+ vs. -)

0.770 (0.501-1.183)

0.2328

HER2 (+ vs. -)

1.162 (0.437-2.577)

0.7395

2.002 (0.591-5.117)

0.2347

0.518 (0.080-1.954)

0.3613

Bcl-2 (+ vs. -)

0.929 (0.604-1.449)

0.7430

0.892 (0.561-1.450)

0.6377

1.745 (0.576-4.804)

0.3078

1.958 (0.621-5.682)

0.2387

Mortality

PostM vs. PreM

1.084 (0.659-1.822)

0.7532

1.482 (0.863-2.646)

0.1568

0.991 (0.335-2.923)

0.9871

0.869 (0.257-2.898)

0.8166

T (>2cm vs. ≤2cm)

2.498 (1.468-4.506)

0.0005*

2.114 (1.198-3.951)

0.0090*

8.196 (1.545-152.292)

0.0093*

10.872 (1.682-234.909)

0.0081*

LN (+ vs. -)

2.861 (1.768-4.778)

<0.0001*

2.997 (1.733-5.430)

<0.0001*

1.826 (0.565-6.013)

0.3097

3.070 (0.845-12.889)

0.0888

Grade (II+III vs. I)

1.849 (1.118-3.168)

0.0161*

2.184 (1.258-3.969)

0.0051*

1.079 (0.312-4.332)

0.9076

1.299 (0.367-5.344)

0.6924

ER (+ vs. -)

1.354 (0.714-2.696)

0.3614

PR (+ vs. -)

0.564 (0.342-0.920)

0.0219*

HER2 (+ vs. -)

1.188 (0.440-2.697)

0.7099

1.968 (0.577-5.095)

0.2486

0.536 (0.074-2.341)

0.4345

Bcl-2 (+ vs. -)

0.801 (0.496-1.307)

0.3695

0.688 (0.415-1.161)

0.1591

2.550 (0.797-7.752)

0.1106

3.443 (0.999-11.894)

0.0502